Breast Cancer Gene Patents Challenged

  • Playlist
  • Download
  • Embed
    Embed <iframe src="http://www.npr.org/player/embed/121343433/121343429" width="100%" height="290" frameborder="0" scrolling="no">
  • Transcript

A landmark lawsuit is challenging the patents Myriad Genetics holds on the so-called breast cancer genes — patents that make Myriad the sole provider of a crucial genetic test. Do patents on genes spur research and innovation, or harm patients? Two experts share their views.

Guests:

Kevin Noonan, patent attorney, molecular biologist, partner, McDonnell, Boehnen, Hulbert & Berghoff, LLP, Chicago, Ill.

Daniel Ravicher, executive director, Public Patent Foundation, lecturer in law and associate director, Intellectual Property Law Program, Benjamin N. Cardozo School of Law, New York, N.Y.

Related NPR Stories

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.